Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including other brain neurons; strongest in syncytiotrophoblasts | 0.75 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 2 Parkinson's papers of 613 | 0.85 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 8905
Sealed predictions
- PEG3 in dopamine neurons, braak-0.13 (p 0.732) → +0.50 (p 0.175)receipt 8912
Swarm cases
receipt 8912: PEG3 in dopamine neurons, braak
- power
- full sample +0.25 (p 0.310, n 18), 95% CI -0.24 to +0.64. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.21 (p 0.393, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.27 (p 0.273, n 18). could be the mix.
- skeptic
- leave-one-out range +0.18 to +0.44, sign flips 0; without severely affected donors +0.25 (p 0.310, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for PEG3 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts